Johnson & Johnson (JNJ)

137.52
1.00 0.72
NYSE
Prev Close 138.52
Open 139.35
Day Low/High 135.75 / 140.24
52 Wk Low/High 118.62 / 148.99
Volume 10.18M
Exchange NYSE
Shares Outstanding 2662.77B
Market Cap 367.52B
Div & Yield N.A. (N.A)
Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

What's Valeant Worth Without Salix?

What's Valeant Worth Without Salix?

The debt-laden drugmaker needs to shore up cash, but a Salix sale might be too rash a move.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Technical Picture Remains Mixed

Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...

Dependable Johnson & Johnson Needs a Band-Aid

Dependable Johnson & Johnson Needs a Band-Aid

Charts suggest that JNJ has further downside risk.

Cramer: What a Democratic Sweep Would Mean for Stocks

Cramer: What a Democratic Sweep Would Mean for Stocks

For starters, trouble for banks, drugs, energy and M&A.

Jim Cramer Reflects on the Anniversary of the Black Monday Market Crash

Jim Cramer Reflects on the Anniversary of the Black Monday Market Crash

Jim Cramer reflects on a dramatic day of selling on Wall Street that forever changed the industry.

The Good, the Bad and the Ugly

"I've never seen so many men wasted so badly." -- Blondie in The Good, the Bad and the Ugly." And now it's time to run down "The Good, the Bad and the Ugly" ...   The Good The market was up from the get-go. (T)FANG is the world's fair. High beta was...

Midday Musings From Sir Arthur Cashin

Back at morning highs and facing mild resistance at S&P 500 Index 2145/2149. WTI above $50 seems to put a bid under stocks, below $50 not so much. Stocks here and across the pond helped by rumors that sovereign funds may buy more equities. Volume a ...

Midday Report: UnitedHealth Tops Third Quarter; Netflix Drives Nasdaq Higher

Midday Report: UnitedHealth Tops Third Quarter; Netflix Drives Nasdaq Higher

U.S. stocks held higher as a series of positive earnings reports filtered in on Tuesday. Netflix boosted the Nasdaq, while Goldman Sachs pushed the Dow Jones Industrial Average higher.

Markets Await Goldman Sachs and Yahoo! Earnings on Tuesday

Markets Await Goldman Sachs and Yahoo! Earnings on Tuesday

On Tuesday, October 18, Goldman Sachs (GS) and Yahoo! (YHOO) release quarterly results.

Walk Away From This Market

In "The Market Outlook Worsens," I made the following observations:  When I throw in a dose of the following headwinds, the stage could be set for a difficult three to nine months for the capital markets: Overvaluation, with 25x GAAP and 19x non-GAA...

What to Watch on Wall Street This Week: Netflix Earnings, Fed Speakers

What to Watch on Wall Street This Week: Netflix Earnings, Fed Speakers

Investors will get a slew of earnings reports from major companies and a host of Federal Reserve speakers during the week of Oct. 17.

Samsung's Double Recall Will Enter Textbooks as Crisis Management Disaster

Samsung's Double Recall Will Enter Textbooks as Crisis Management Disaster

The dual recall of both new and replacement Galaxy Note7 phones has left Samsung Electronics shares in tatters.

Cramer: This Is a Market of Stocks, not a Market of Markets

Cramer: This Is a Market of Stocks, not a Market of Markets

Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Cramer: The Stock Market Is Helping the Consumer This Year

Cramer: The Stock Market Is Helping the Consumer This Year

It could well be the stock market, not the Fed, that is driving our retail and services.

J&J: Don't Overpay for Lukewarm Results

J&J: Don't Overpay for Lukewarm Results

Its long-term reputation appears to be supporting the shares far more than they deserve.

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.

Zimmer Biomet and NuVasive Could be a Spine-Tingling Combination

Zimmer Biomet and NuVasive Could be a Spine-Tingling Combination

Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.

Don't Disrespect This Bull Market

Don't Disrespect This Bull Market

There are plenty of doubters about the market and its record highs.

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

Closing Bell: S&P Cuts Outlook on Deutsche; Dow Seals New Record

Closing Bell: S&P Cuts Outlook on Deutsche; Dow Seals New Record

Better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record.

Cramer: In Earnings Tests, JNJ Gets an A While Netflix Flunks

Cramer: In Earnings Tests, JNJ Gets an A While Netflix Flunks

It depends on the type of test and who's doing the grading.

Midday Report: Monsanto Rebuffs Bayer Again; S&P 500 Declines

Midday Report: Monsanto Rebuffs Bayer Again; S&P 500 Declines

A rush of earnings kept investors busy throughout the morning. Netflix was one of the biggest drags on the Nasdaq and S&P 500.

Johnson & Johnson Has an Impressive Growth Story, Says Jim Cramer

Johnson & Johnson Has an Impressive Growth Story, Says Jim Cramer

Johnson & Johnson's earnings reveal just how impressive growth is at the big pharma company, according to Jim Cramer.

Johnson & Johnson Tops Earnings Estimates

Johnson & Johnson Tops Earnings Estimates

The health care giant's quarterly earnings and sales clocked in well above analyst expectations.

Morning Movers: NFLX, JNJ, VMW, GES

Morning Movers: NFLX, JNJ, VMW, GES

Netflix underwhelmed analysts as subscriber growth came up short.

What to Watch Tuesday: Goldman Sachs Earnings, June Housing Starts

What to Watch Tuesday: Goldman Sachs Earnings, June Housing Starts

On Tuesday, July 19, investors will focus on the U.S. banking sector when Goldman Sachs reports second quarter results.